Objective To derive an optimal liver stiffness measurement cut point to discriminate METAVIR fibrosis stage F4 and to validate both METAVIR fibrosis stage F3-F4 and F4 cut points in a separate cohort. Results In total, 267 subjects were enrolled (97 calibration, 170 validation). The cohorts were similar with 54% male, aged 0-29 years (median 13 years), and liver diseases including 21% autoimmune, 19% viral, 11% nonalcoholic fatty liver, 9% cholestatic, and 9% primary sclerosing cholangitis. Cut points to discriminate F3-F4 and F4 were >8.6 kPa and >11.5 kPa with 81% and 84% accuracy, respectively. Applied to the validation cohort, accuracy was 67% and 75%, respectively. In 44 fasted subjects, the accuracy was 73% and 80%, respectively.
L
iver fibrosis is associated with complications, morbidity, and mortality in chronic liver disease. Histopathologic assessment of fibrosis on liver biopsy remains the reference standard for determining the severity of fibrosis yet is associated with complications and sampling error. [1] [2] [3] [4] Moreover, children are exposed to additional risks with liver biopsy as the result of the need for anesthesia or sedation and possibly postprocedure hospitalizations. Transient elastography is an ultrasoundbased tool that has been shown to rapidly and reproducibly measure liver stiffness, which reflects hepatic fibrosis. 5, 6 Multiple studies have shown that liver stiffness measurement by transient elastography can predict hepatic fibrosis in children with various chronic liver diseases. [7] [8] [9] [10] Each study has reported slightly different liver stiffness measurement cut points to identify advanced fibrosis. These studies involved smaller sample sizes, use of limited patient populations, and mainly used the adult, mediumsized probe only. We reported an optimal liver stiffness measurement cut point >8.6 kPa to detect METAVIR fibrosis stage F3-F4 with a high area under the receiver operator characteristic curve (AUROC = 0.84). 7 Although cut points have been validated in adult populations, these cut points have not been validated in pediatric populations with liver disease. 11 The aim of the present study was to validate our previously reported liver stiffness measurement cut point to detect advanced liver fibrosis (F3-F4) in children and young adults. In addition, we aimed to identify and validate an additional liver stiffness measurement cut point to detect cirrhosis (F4) in children and young adults. Although there are many published reports that have used transient elastography in children, most do not include the reference standard assessment for comparison.
Methods
This was a prospective 2-phase study of unselected children and young adults at Boston Children's Hospital who underwent liver stiffness measurements over a 10-year period from 2006 to 2016. All patients were required to have had a liver biopsy within 12 months of enrollment and been available to a study investigator for recruitment. Patients who had an uninterpretable or unavailable biopsy 
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specimen, who lacked critical clinical and/or biochemical data, or who were not candidates for transient elastography because of a technically invalid measurement, ascites, morbid obesity (body mass index >40 kg/m 2 ), pregnancy, or implantable cardiac device were excluded according to the manufacturer's guidelines. Patients who had undergone Fontan surgery also were excluded, given the known high degree of hepatic stiffness in these patients. 12, 13 The calibration cohort included patients enrolled from August 2006 to April 2011 who were used to develop liver stiffness measurement cut points for discriminating F3-F4 and F4 fibrosis. Patients enrolled from April 2011 to March 2016 comprised the validation group and were used to test the diagnostic accuracy of these cut points. This study was approved by the Boston Children's Hospital institutional review board. Written informed consent was obtained from parents, legal guardians, or patients ≥18 years of age. Patient assent was obtained when appropriate.
Liver Histology
All patients underwent liver biopsy for clinical indications. The METAVIR system was used to stage fibrosis by 5 hepatopathologists blinded to liver stiffness measurement. Scoring to stage liver fibrosis was as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Scores of F3 or F4 were considered advanced fibrosis.
Liver Stiffness Measurements
Liver stiffness was measured by transient elastography (FibroScan, Echosens, Paris, France), an ultrasound-based technique that involves placing an ultrasonic transducer in a right intercostal space to transmit a vibration of mild amplitude and low frequency. The vibration on the skin surface creates a shear wave that propagates through the right lobe of the liver. The velocity of propagation is related directly to tissue stiffness; the harder the tissue (as in hepatic fibrosis), the faster the shear wave propagates. Eight to ten valid liver stiffness measurements were obtained and reported as a median value in kilopascals. Adequacy of measurement was assessed by the transient elastography device. Liver stiffness measurement was performed by 6 trained study investigators who were certified by the manufacturer and blinded to the liver biopsy results. Transient elastography probe size selection was based on thoracic perimeter (TP); the medium probe was used if TP was >75 cm and the small (S) if TP ≤75 cm. Before November 2009, when the S probe became available, no patients weighing <50 pounds were included. Box-whisker plots were used to illustrate the distribution of liver stiffness measurement across the 5 METAVIR stages, and comparisons between the calibration and validation cohorts were made by the Student t test. Differences in liver stiffness measurement within each METAVIR stage were investigated with 2-way ANOVA using an interaction term for cohort and METAVIR. Although liver stiffness measurement was rightskewed, results from nonparametric analysis and analysis of liver stiffness measurement after transforming to normal scores were consistent with the parametric results, and only the latter are reported. 14 The calibration cohort was used to construct receiver operating characteristic curves to evaluate the ability of transient elastography to discriminate METAVIR stages F3-F4 from stages F0-F2 and F4 from stages F0-F3. The AUROC is reported with a 95% CI to compare the curve with the diagonal (AUROC = 0.5, indicating predictive ability no better than a coin flip). An optimal cut point was determined by minimizing the probability of a false-positive transient elastography result and maximizing the probability of a true-positive transient elastography result. These cut points were then used to construct 2 × 2 contingency tables comparing the disease status (presence/absence based on METAVIR dichotomy) to the transient elastography result (positive/negative based on cut point dichotomy). Diagnostic performance of transient elastography was assessed by sensitivity, specificity, accuracy, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio and shown with 95% CI. 15, 16 Validation was assessed for the entire validation cohort as well as for a subgroup of subjects who fasted before transient elastography. Diagnostic performance characteristics were compared by the Fisher exact test.
Statistical Analyses
All data analysis was performed and figures prepared with SAS, version 9.4 (SAS Institute, Cary, North Carolina). All tests of significance were 2-sided, with P < .05 indicating statistical significance.
Results
A total of 321 subjects were screened from 2006 to 2016, of whom 54 (17%) were excluded due to inability to obtain a valid liver biopsy or liver stiffness measurement, resulting in a sample of 267 subjects available for analysis (Figure 1 ; available at www.jpeds.com). The calibration cohort used to determine optimal cut points for discriminating F3-F4 and F4 fibrosis consisted of 97 subjects 7 ; the cut points were validated by using a cohort of 170 subjects.
Demographic characteristics of the study population and primary diagnostic indications for liver biopsy are shown in Table I . In total, 230 subjects (86%) were <18 years of age. Subjects in the validation cohort were less likely to be of white race (59% vs 72%; P = .03) and to have had a liver transplant (1% vs 5%; P = .03) than those in the calibration cohort. The distribution of characteristics was otherwise statistically similar across the 2 cohorts. All METAVIR stages were well represented. Approximately one-third of subjects had advanced fibrosis (stage F3-F4), 35% in the calibration cohort and 28% in the validation cohort (P = .25).
Volume 198 • July 2018 Figure 2 shows the distribution of liver stiffness measurement scores by METAVIR stage F0-F4 in both the calibration and validation cohorts. Although the protocol specified that liver stiffness measurement was to be obtained within 1 year of biopsy, the median interval between the time of biopsy and liver stiffness measurement was only 46 days (IQR 19-130), with 81% of subjects having the liver stiffness measurement performed within 6 months of biopsy. Liver stiffness 
THE JOURNAL OF PEDIATRICS •
3 ± 1.4 compared with the validation cohort of 12.8 ± 1.1 (P = .80 by t test). There was no difference between cohorts when examined within METAVIR stages (P = .78 by ANOVA 2-way interaction). However, although liver stiffness measurement was statistically similar among METAVIR stages F0-F2 for both cohorts combined (P ≥ .20 for all pairwise comparisons among F0, F1, and F2), liver stiffness measurement for F3 was on average 4.0 kPa greater than the mean liver stiffness measurement for F0-F2 (13.7 ± 1.8 vs 9.7 ± 0.9 kPa, P = .05), and liver stiffness measurement for F4 was more than double the mean for F0-F2 (26.6 ± 2.0 vs 9.7 ± 0.9 kPa, P < .0001; comparisons not shown). Cut points were derived from receiver operating characteristic curves to predict F3-F4 (advanced fibrosis) and F4 (cirrhosis) by the use of data from the calibration cohort. Optimal cut points to predict advanced fibrosis and cirrhosis were determined to be liver stiffness measurement >8.6 kPa and >11.5 kPa, respectively, with AUROCs of 0.85 (95% CI 0.76-0.93) and 0.87 (95% CI 0.79-0.96) (Figure 3 ; available at www.jpeds.com). Diagnostic performance characteristics for these cut points are shown in Table II for both the calibration and validation cohorts. The accuracy for predicting F3-F4 advanced fibrosis and F4 fibrosis in the calibration cohort was 81.4% (95% CI 72.3%-88.6%) and 83.5% (95% CI 74.6%-90.3%), respectively, compared with 67.1% (95% CI 59.4%-74.1%) and 75.3% (95% CI 68.1%-81.6%) in the validation cohort.
Because the importance of at least 3 hours of fasting before liver stiffness measurement was demonstrated in adult studies while data collection for the validation cohort was already underway, the protocol was amended to include fasting status and is available for 44 (26%) validation subjects. Analysis of variance was used to investigate differential effects in the calibration cohort or METAVIR status by fasting. Differences were found only for the main effect of METAVIR status; no differences were attributable to fasting (P = .76) ( Table III; available at www.jpeds.com). With fasting, accuracy for the F3-F4 advanced fibrosis and F4 cirrhosis cut points was 72.7% (95% CI 57.2%-85.0%) and 79.5% (95% CI 64.7%-90.2%), respectively (Table IV) .
Discussion
Transient elastography is a tool used to measure liver stiffness and has been shown to rapidly and reliably assess fibrosis in adults and children. There have been several studies in which the authors used transient elastography to measure liver stiffness measurement in children with various liver diseases, with differing cut points for advanced fibrosis. Some of the variability in published cut points has likely been the result of studies of patients with specific liver diseases, unavailability of the S probe for smaller children, and the under-representation of advanced fibrosis.
This study evaluated a previously published liver stiffness measurement cut point and validated its performance in an .03
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Performance characteristics include sensitivity (Sn), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), accuracy (Ac), positive likelihood ratio (LR+), and negative likelihood ratio (LR−). Numbers in parentheses represent the 95% CI. P value from the Fisher exact test.
independent pediatric cohort. Overall, liver stiffness measurement diagnostic performance characteristics were better for the calibration cohort in comparison with the validation cohort. However, the differences in diagnostic performance between the calibration and validation cohorts were only statistically different for positive predictive value (both cut points), specificity (F3-F4 cut point only), and accuracy (F3-F4 cut point only). There were no statistical differences in diagnostic performance between the calibration and fasting cohort, reflecting both improved performance and potentially reduced power due to a reduction in sample size. Our results were similar to that of a validation study of transient elastography in adults. In 2015, a prospective 2-phase, multicenter study of transient elastography in adult patients with chronic hepatitis C or B included 188 subjects in the developmental phase and 560 subjects in the validation phase. 11 In phase 1, the cut point to predict F2 fibrosis or greater was 8.4 kPa with AUROC 0.89, 82% sensitivity, 79% specificity, and to predict F4 fibrosis was 12.8 kPa with AUROC 0.92, 84% sensitivity, 86% specificity. When these cut points were tested in the validation cohort, the F2 fibrosis or greater cut point had 58% sensitivity, 75% specificity and for the F4 fibrosis cut point 76% sensitivity and 85% specificity.
This study has several limitations. This study cohort includes a heterogeneous group of patients with liver disease. The study performed in an array of diseases is representative of those seen in our clinical practice but may over-or underestimate accuracy in any particular disorder or type of disorder. Another study limitation is potential selection bias. Many patients who underwent liver biopsy were not available to recruitment, which could have resulted in selection bias. In addition, 44 subjects had liver stiffness measurements that either could not be obtained or were not valid, thus also introducing potential selection bias in the cohort. Although an additional confounding factor could be the possibility of changing status of liver disease in the interim between liver biopsy and liver stiffness measurement, the median time between liver biopsy and liver stiffness measurement was only 46 days (IQR 9-130 days), with 81% of subjects having liver stiffness measurement within 6 months of their biopsy. In addition, although liver biopsies were reviewed by 5 blinded hepatopathologists, they used a validated, standardized histologic scoring system, thereby minimizing inter-observer variability.
Unfortunately, the importance of fasting was not established until the validation protocol was underway, and liver stiffness measurement under fasting conditions is not available uniformly for all subjects. As noted, the manufacturer now recommends fasting for at least 3 hours before liver stiffness measurement due to potential overestimation of liver stiffness measurement in the postprandial state. Because these recommendations were not published until after the completion of the calibration study, this could have resulted in compromise of the accuracy of liver stiffness measurement and the derived cut points. Similarly, recent studies in adults and children have shown that liver stiffness measurement can be further confounded by other components of liver disease. Some of these studies highlight the association between hepatic Table IV inflammation and the overestimate of liver stiffness measurement by transient elastography. [17] [18] [19] This study validates liver stiffness measurement cut points of 8.6 kPa and 11.5 kPa to predict advanced fibrosis and cirrhosis in separate cohorts of children and young adults with liver disease. Transient elastography has been known to be a safe, well-tolerated technique in both adults and children. With this new information, more formal guidelines can be developed to help use transient elastography values within clinical practice to help identify those pediatric patients with advanced fibrosis or cirrhosis. When used in combination in clinical data, transient elastography could be used to assess the risk of cirrhosis in children. With increasing data on the utility and validity of liver stiffness measurement in children, transient elastography may help identify those patients with greater risk of advanced fibrosis and those who need liver biopsy assessment and/or surveillance for the complications of cirrhosis in a variety of liver disorders. ■ Mean liver stiffness measurement differs across METAVIR levels (P < .0001) but does not depend on fasting status within METAVIR levels (P = .99). There were no differences in mean liver stiffness measurement attributable to fasting by cohort (P = .76). Results are from 2 ANOVA models, one to assess mean liver stiffness measurement by cohort and fasting status and a second to assess mean liver stiffness measurement by METAVIR and fasting status. An interaction term was used to investigate whether any effect in fasting status depended on the group variable (cohort or METAVIR status)
